Project Grant R01CA292020
Award Date 7/1/24
Completion Date 6/30/29
Dollars Obligated $939K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Columbus, OH 43210, USA
Similar Awards
- This $214,583 Project Grant awarded by the National Cancer Institute (CFDA 93.393 - Cancer Cause and Prevention Research) to Tulane University will fund research to evaluate the role of the extracellular matrix in triple-negative breast cancer (TNBC) progression and treatment response, with a focus on African American patient populations. The research aims to provide insights on key extracellular matrix proteins that regulate TNBC tumorigenesis, metastasis, and response to therapy, using 3D in...
- This $3.3 million project grant from the National Cancer Institute's Cancer Cause and Prevention Research program (CFDA 93.393) supports research to identify prediagnostic exposures, germline genetics, and immune and mutational profiles associated with triple negative breast cancer (TNBC). Joan & Sanford I Weill Medical College of Cornell University is the primary awardee and will perform whole exome sequencing of tumor and germline DNA from 400 TNBC patients across four prospective cohort...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $631,492 to support research at the University of Kentucky Research Foundation aimed at identifying nicotinamide N-methyltransferase (NNMT) as a new target to treat triple-negative breast cancer (TNBC). The 5-year project, awarded on April 7, 2025 and scheduled for completion by March 31, 2030, will: Define how NNMT promotes anchorage-independent growth and protects TNBC cells...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $619,764 to the University of Wisconsin - Madison to develop new combination immunotherapy strategies for treating triple-negative breast cancer (TNBC). The key objectives are to: 1) increase the tumor-selective accumulation of a platelet-mediated immune checkpoint inhibitor (P-aPDL1) by triggering local thrombus formation in TNBC tumors, and 2) modulate the immunosuppressive...
- The U.S. National Cancer Institute (NCI) awarded a $400,000 Project Grant under the Cancer Treatment Research federal grant program (CFDA 93.395) to Promilead, LLC for the project "ACTIVATING TFEB TO ENHANCE THE EFFICACY OF IMMUNOTHERAPY FOR TRIPLE NEGATIVE BREAST CANCER". The project aims to investigate the tumor suppressive role of the transcription factor TFEB and its potential to enhance the efficacy of immune checkpoint inhibitor (ICI) immunotherapy for the treatment of triple...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $164,500 to The Trustees of Columbia University in the City of New York to investigate the mechanisms by which the protein S100A9 mediates brain metastasis in epidermal growth factor receptor (EGFR)-mutant lung cancer. The key goals are to: Examine how S100A9 expression is epigenetically regulated by histone methylation and the MEIS1 transcription factor in brain metastasis-prone cells....
- The National Cancer Institute (NCI) awarded a 5-year, $676,584 Project Grant under the Cancer Biology Research program (CFDA 93.396) to The University of Texas MD Anderson Cancer Center (MD Anderson). The grant aims to investigate the genomic evolution and tumor microenvironment dynamics that drive metastatic progression in triple-negative breast cancer (TNBC). Specifically, the project will leverage a postmortem tissue collection program and advanced single-cell genomics techniques to...
- This $412,054 federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) will support research at New York University (NYU) to dissect the role of the immune microenvironment in melanoma bone metastasis. The funded research aims to utilize preclinical murine models to define the mechanisms by which melanoma cells colonize the skeletal system and modify the bone microenvironment. Key objectives include examining the role of bone...
- The National Cancer Institute awarded a Project Grant of $151,040.00 to the Dana-Farber Cancer Institute, Inc. (DFCI) under the Cancer Research Manpower (CFDA 93.398) federal grant program. The project, titled "Interrogating the Role of IFNgamma in Promoting Metastasis and Immune Evasion of Triple Negative Breast Cancer," aims to study how interferon gamma (IFNγ) signaling regulates the ability of triple negative breast cancer (TNBC) cells to evade the immune system and establish...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides funding to the University of Colorado-Denver to study the role of the EYA3/PP2A protein complex in regulating the metastatic spread of triple-negative breast cancer (TNBC). The $647,118 award, effective March 1, 2025 through February 28, 2030, supports research aimed at understanding how EYA3 and its interaction with the B55A subunit of PP2A contribute to TNBC metastasis. The project...